Spirit Scientific Co

Spirit Scientific Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Spirit Scientific Co (7790.TWO) as of Oct 30, 2026 is -843.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 241.21 % — a change of -449.77% (lower).

FCF Conversion

-843.66 %

YoY

-449.77%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Spirit Scientific Co is 2024 -843.66 % . FCF Conversion Rate (FCF/EBITDA) of Spirit Scientific Co was 2023 241.21 % . It decreases by -449.77% lower compared to the previous year.

The Spirit Scientific Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2022
202.70 TWD
Jan 1, 2023
241.21 TWD
Jan 1, 2024
-843.66 TWD
The Spirit Scientific Co FCF Conversion history
YEARFCF ConversionYoY
-843.66 %-449.77%
241.21 %+19.00%
202.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Spirit Scientific Co Stock analysis

What does Spirit Scientific Co do? Spirit Scientific Co Ltd generates revenue through autologous Platelet Lyophilized Technology (PLT) cryo-crystal preparation services and autologous high-concentration platelet gel preparation services. The company also offers clinical research cooperation commission services, blood-related commissioned manufacturing, biomaterial-type cryo-crystal testing or commissioned manufacturing, biomaterial-type cosmetic raw material production, and biomaterial-type cryo-crystal laboratory construction consulting services. These services are primarily sold to healthcare providers and research institutions within Taiwan, focusing on biomaterial separation, purification, mass production, and standardized process development for biotechnology applications. The firm's main products target the health care equipment and supplies industry, with a strong emphasis on growth factor cryo-crystal related solutions. Their services are tailored to meet the needs of clients seeking advanced biotechnology services, including the development of biomaterial-type cryo-crystals and cosmetic raw materials. Spirit Scientific operates exclusively in Taiwan, serving local healthcare and research sectors with specialized biotechnology offerings. Revenue streams include both service-based contracts for cryo-crystal preparation and manufacturing, as well as consulting services for laboratory construction. The company’s focus on biomaterial separation, purification, and dosage form improvement drives demand from clients requiring standardized biotechnology processes. All services are delivered within Taiwan, aligning with the firm's exclusive market presence. Spirit Scientific Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Spirit Scientific Co stock

FCF Conversion Rate (FCF/EBITDA) of Spirit Scientific Co is -843.66 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Spirit Scientific Co changed from 241.21 % to -843.66 %, representing a -449.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Spirit Scientific Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Spirit Scientific Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Spirit Scientific Co

All Key Metrics — Spirit Scientific Co